RTP Mobile Logo
Breast Cancer Update: Nursing Edition, Issue 1, 2010
Released July 2010

Featuring interviews with Kimberly L Blackwell, MD, Erin Duff, MSN, ANP-BC, Kathy D Miller, MD, Christina M Brown, RN, BSN and Hope S Rugo, MD and additional comments by three women with breast cancer. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Breast cancer is one of the most rapidly evolving fields in oncology nursing. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances, the efficacy of new agents and regimens and strategies to minimize and manage associated toxicities. This program provides nurses with access to the latest research developments in systemic therapy and the opinions of oncology nurses and clinical investigators with experience and expertise in the field, in addition to perspectives of patients undergoing treatment.

    PURPOSE STATEMENT

    To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

    EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF BREAST CANCER UPDATE FOR NURSES

    • Describe the evidence-based benefits and risks associated with systemic therapies, including chemotherapy, PARP inhibitors and endocrine and biologic agents, used in the treatment of breast cancer in the neoadjuvant, adjuvant and metastatic settings.
    • Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
    • Explain the advantages and limitations of available genomic assays to quantify recurrence risk and aid in adjuvant treatment decisions.
    • Discuss the psychosocial and emotional needs of patients and their loved ones, in addition to healthcare professionals, associated with the diagnosis and management of breast cancer.

    ACCREDITATION STATEMENT

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CNE ACTIVITY

    CME credit is no longer available for this issue

    This is an audio CNE program. This website contains CNE information, including learning objectives and faculty disclosures, as well as links to relevant abstracts and full-text articles.

    The participants should read the learning objectives and faculty disclosures and listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYMs Duff and Ms Brown had no real or apparent conflicts of interest to disclose. Dr BlackwellConsulting Agreements and Speakers Bureau: GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Paid Research: Abraxis BioScience, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline. Dr MillerAdvisory Committee: Genentech BioOncology, MethylGene Inc, Roche Laboratories Inc; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc. Dr RugoSpeakers Bureau: AstraZeneca Pharmaceuticals LP.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Genentech BioOncology and Genomic Health Inc.


    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2010
    Expiration date: July 2011

Acknowledge and close

Breast Cancer Update: Nursing Edition, Issue 1, 2010
Released July 2010

Featuring interviews with Kimberly L Blackwell, MD, Erin Duff, MSN, ANP-BC, Kathy D Miller, MD, Christina M Brown, RN, BSN and Hope S Rugo, MD and additional comments by three women with breast cancer. (Audio Content)